Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation

Background: Some smokers may benefit from a therapy that combines different nicotine replacement therapies (NRT) or drugs with different mechanisms of action. The aim of this study was to determine the efficacy of the combined therapy of varenicline and nicotine patches versus varenicline monotherap...

Descripción completa

Detalles Bibliográficos
Autores: Ramon Torrell, Josep M. (Josep Maria), Morchón Ramos, Sergio, Baena, Antoni, Masuet Aumatell, Cristina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2014
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/120276
Acceso en línea:https://hdl.handle.net/2445/120276
Access Level:acceso abierto
Palabra clave:Nicotina
Tabac
Hàbit de fumar
Fumadors
Nicotine
Tobacco
Smoking
Cigarette smokers
id ES_4fd89507938510e42ebfc5451d2d4ccd
oai_identifier_str oai:diposit.ub.edu:2445/120276
network_acronym_str ES
network_name_str España
repository_id_str
spelling Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessationRamon Torrell, Josep M. (Josep Maria)Morchón Ramos, SergioBaena, AntoniMasuet Aumatell, CristinaNicotinaTabacHàbit de fumarFumadorsNicotineTobaccoSmokingCigarette smokersBackground: Some smokers may benefit from a therapy that combines different nicotine replacement therapies (NRT) or drugs with different mechanisms of action. The aim of this study was to determine the efficacy of the combined therapy of varenicline and nicotine patches versus varenicline monotherapy. Methods: Three hundred forty-one smokers who smoked 20 or more cigarettes per day were recruited from a smoking cessation clinic between February 2012 and June 2013. The participants were randomized to receive a varenicline plus nicotine patch of 21 mg every 24 hours (170) or varenicline plus a placebo patch (171). All of the smokers received a standard 12-week course of varenicline and an 11-week course of either the placebo patch or the active patch after the target quit day. Both groups received behavioral support. The primary outcome was continuous abstinence for weeks 2 through 12 confirmed by exhaled levels of carbon monoxide. Post hoc subgroup analyses were performed to evaluate the treatment effects for a specific endpoint in subgroups of smokers. Results: The combination of the nicotine patch with varenicline was not associated with higher rates of continuous abstinence at 12 weeks (39.1% versus 31.8%; odds ratio (OR) 1.24; 95% confidence interval (CI) 0.8 to 2.6) and 24 weeks (32.8% versus 28.2%; OR 1.17; 95% CI 0.4 to 1.9). When participants were analyzed by subgroups according to cigarette consumption, the abstinence rates among smokers who smoked more than 29 cigarettes per day at 12 weeks (OR 1.39; 95% CI 1.2 to 2.5) and 24 weeks (OR 1.46; 95% CI 1.2 to 2.8) were significantly higher in the combination group. Other post hoc analyses based on level of dependence and previous quit attempts did not show subgroup differences. No differences between the groups for the reported adverse events were observed (χ2 value 0.07; P 0.79). Conclusions: The combination of varenicline with the nicotine patch does not improve abstinence rates at 12 and 24 weeks compared with varenicline used as monotherapy when all smokers were analyzed as a whole, independent of consumption level.BioMed Central2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/120276Articles publicats en revistes (Ciències Clíniques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1186/s12916-014-0172-8BMC Medicine, 2014, vol. 12, p. 172https://doi.org/10.1186/s12916-014-0172-8cc-by (c) BioMed Central, 2014http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1202762026-05-27T06:46:51Z
dc.title.none.fl_str_mv Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
title Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
spellingShingle Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
Ramon Torrell, Josep M. (Josep Maria)
Nicotina
Tabac
Hàbit de fumar
Fumadors
Nicotine
Tobacco
Smoking
Cigarette smokers
title_short Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
title_full Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
title_fullStr Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
title_full_unstemmed Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
title_sort Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation
dc.creator.none.fl_str_mv Ramon Torrell, Josep M. (Josep Maria)
Morchón Ramos, Sergio
Baena, Antoni
Masuet Aumatell, Cristina
author Ramon Torrell, Josep M. (Josep Maria)
author_facet Ramon Torrell, Josep M. (Josep Maria)
Morchón Ramos, Sergio
Baena, Antoni
Masuet Aumatell, Cristina
author_role author
author2 Morchón Ramos, Sergio
Baena, Antoni
Masuet Aumatell, Cristina
author2_role author
author
author
dc.subject.none.fl_str_mv Nicotina
Tabac
Hàbit de fumar
Fumadors
Nicotine
Tobacco
Smoking
Cigarette smokers
topic Nicotina
Tabac
Hàbit de fumar
Fumadors
Nicotine
Tobacco
Smoking
Cigarette smokers
description Background: Some smokers may benefit from a therapy that combines different nicotine replacement therapies (NRT) or drugs with different mechanisms of action. The aim of this study was to determine the efficacy of the combined therapy of varenicline and nicotine patches versus varenicline monotherapy. Methods: Three hundred forty-one smokers who smoked 20 or more cigarettes per day were recruited from a smoking cessation clinic between February 2012 and June 2013. The participants were randomized to receive a varenicline plus nicotine patch of 21 mg every 24 hours (170) or varenicline plus a placebo patch (171). All of the smokers received a standard 12-week course of varenicline and an 11-week course of either the placebo patch or the active patch after the target quit day. Both groups received behavioral support. The primary outcome was continuous abstinence for weeks 2 through 12 confirmed by exhaled levels of carbon monoxide. Post hoc subgroup analyses were performed to evaluate the treatment effects for a specific endpoint in subgroups of smokers. Results: The combination of the nicotine patch with varenicline was not associated with higher rates of continuous abstinence at 12 weeks (39.1% versus 31.8%; odds ratio (OR) 1.24; 95% confidence interval (CI) 0.8 to 2.6) and 24 weeks (32.8% versus 28.2%; OR 1.17; 95% CI 0.4 to 1.9). When participants were analyzed by subgroups according to cigarette consumption, the abstinence rates among smokers who smoked more than 29 cigarettes per day at 12 weeks (OR 1.39; 95% CI 1.2 to 2.5) and 24 weeks (OR 1.46; 95% CI 1.2 to 2.8) were significantly higher in the combination group. Other post hoc analyses based on level of dependence and previous quit attempts did not show subgroup differences. No differences between the groups for the reported adverse events were observed (χ2 value 0.07; P 0.79). Conclusions: The combination of varenicline with the nicotine patch does not improve abstinence rates at 12 and 24 weeks compared with varenicline used as monotherapy when all smokers were analyzed as a whole, independent of consumption level.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/120276
url https://hdl.handle.net/2445/120276
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1186/s12916-014-0172-8
BMC Medicine, 2014, vol. 12, p. 172
https://doi.org/10.1186/s12916-014-0172-8
dc.rights.none.fl_str_mv cc-by (c) BioMed Central, 2014
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) BioMed Central, 2014
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407844858593280
score 15,300719

Similares en LA Referencia